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Background: Hec1 (NDC80) is an integral part of the kinetochore and is overexpressed in a variety of human
cancers, making it an attractive molecular target for the design of novel anticancer therapeutics. A highly potent
first-in-class compound targeting Hec1, TAI-1, was identified and is characterized in this study to determine its
potential as an anticancer agent for clinical utility.
Methods: The in vitro potency, cancer cell specificity, synergy activity, and markers for response of TAI-1 were
evaluated with cell lines. Mechanism of action was confirmed with western blotting and immunofluorescent
staining. The in vivo potency of TAI-1 was evaluated in three xenograft models in mice. Preliminary toxicity was
evaluated in mice. Specificity to the target was tested with a kinase panel. Cardiac safety was evaluated with hERG
assay. Clinical correlation was performed with human gene database.
Results: TAI-1 showed strong potency across a broad spectrum of tumor cells. TAI-1 disrupted Hec1-Nek2 protein
interaction, led to Nek2 degradation, induced significant chromosomal misalignment in metaphase, and induced
apoptotic cell death. TAI-1 was effective orally in in vivo animal models of triple negative breast cancer, colon cancer
and liver cancer. Preliminary toxicity shows no effect on the body weights, organ weights, and blood indices at
efficacious doses. TAI-1 shows high specificity to cancer cells and to target and had no effect on the cardiac
channel hERG. TAI-1 is synergistic with doxorubicin, topotecan and paclitaxel in leukemia, breast and liver cancer
cells. Sensitivity to TAI-1 was associated with the status of RB and P53 gene. Knockdown of RB and P53 in cancer
cells increased sensitivity to TAI-1. Hec1-overexpressing molecular subtypes of human lung cancer were identified.
Conclusions: The excellent potency, safety and synergistic profiles of this potent first-in-class Hec1-targeted small
molecule TAI-1 show its potential for clinically utility in anti-cancer treatment regimens.
Keywords: Hec1, NDC80, Anti-cancer drug, Therapeutics, Mitosis, Apoptosis, P53, Retinoblastoma gene,
Markers for responseBackground
Drugs that interfere with mitosis are part of the most
successful cancer chemotherapeutic compounds cur-
rently used in clinical practice [1]. Development of che-
motherapeutic drugs that target the mitotic cycle has
focused on inhibition of the mitotic spindle through in-
teractions with microtubules [1]. Drugs targeting micro-
tubules such as taxanes and vinca alkaloids are effective
in a wide variety of cancers, however, the hematopoietic* Correspondence: lynnhuang.lh245@gmail.com
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stated.and neurological toxicities as well as development of re-
sistance to this class of drugs severely limit their long
term clinical utility [1,2]. Novel anti-mitotic agents have
been designed to target the mitotic apparatus through
non-microtubule mitotic mediators such as mitotic ki-
nases and kinesins [2].
A novel attractive non-microtubule target is Highly
Expressed in Cancer 1 (Hec1), a component of the kin-
etochore that regulates the spindle checkpoint. Hec1 is
of particular interest because of its association with can-
cer progression [3-5]. Hec1 directly interacts with mul-
tiple kinetochore components including Nuf2, Spc25,
Zwint-1, and with mitotic kinases Nek2 and Aurora BLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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mal cells and transformed cells during the cell cycle
[4,8]. Rapidly dividing cells express a high level of Hec1,
in contrast to very low to undetectable levels of Hec1 in
terminally differentiated cells [3]. Hec1 has been demon-
strated to overexpress in various human cancers includ-
ing the brain, liver, breast, lung, cervical, colorectal and
gastric cancers [3,9]. From a mechanistic standpoint, tar-
geted inhibition of Hec1 by RNAi or by small molecules
effectively blocks tumor growth in animal models [3,10].
Therefore, Hec1 emerges as an excellent target for
treating cancer clinically.
Small molecules targeting the Hec1/Nek2 pathway was
first discovered by Drs. Chen in the laboratory of Dr. W.
H. Lee using the inducible reverse yeast two-hybrid
screening of a library of ~24,000 compounds [3]. A
series of compounds was designed based on this pub-
lished initial hit molecule as the starting template to
optimize the potency for drug development (Huang
et al., manuscript in preparation). The original template
with micromolar in vitro potency was improved to low
nanomolar potency, enabling possible clinical utility of
the Hec1-targeted compound. This study explores the
features and potential of the improved anticancer agent
targeting Hec1, TAI-1, for preclinical development and
clinical utility. The in vitro and in vivo biological activity,
mechanism of action, toxicity and safety, and transla-
tional implications are investigated.
Methods
Cell lines
MDA-MB-231, MDA-MB-468, K562, HeLa, MCF7,
HCC1954, A549, COLO205, U2OS, Huh-7, U937,
HepG2, KG-1, PC3, BT474, MV4-11, RS4;11, MOLM-
13, WI-38, HUVEC, RPTEC, and HAoSMC were from
Development Center for Biotechnology, New Taipei
City, Taiwan; MDA-MB-453, T47D, ZR-75-1, ZR-75-
30, MDA-MB-361, Hs578T, NCI-H520, Hep3B, PLC/
PRF/5 were from Bioresource Collection and Research
Center, Hsinchu, Taiwan. Cell lines were maintained in
complete 10% fetal bovine serum (Biowest, Miami, FL,
USA or Hyclone, Thermo Scientific, Rockford, IL, USA)
and physiologic glucose (1 g/L) in DME (Sigma, St.
Louis, MO, USA). Studies conducted using cell lines
RPMI8226, MOLT-4, and N87; drug-resistant cell lines
MES-SA/Dx5, NCI/ADR-RES, and K562R were from and
tested by Xenobiotic Laboratories, Plainsboro, NJ, USA.
In vitro potency assay
Cells were seeded in 96 well plates, incubated for 24
hours, compounds added and incubated for 96 hours.
All testing points were tested in triplicate wells. Cell
viability was determined by MTS assay using CellTiter
96® Aqueous Non-radioactive Cell Proliferation Assaysystem (Promega, Madison, WI, USA) according to manu-
facturer’s instructions with MTS (Promega) and PMS
(Sigma, St. Louis, MO). Data retrieved from spectropho-
tometer (BIO-TEK 340, BIOTEK, VT, USA) were processed
in Excel and GraphPad Prism 5 (GraphPad Software, CA,
USA) to calculate the concentration exhibiting 50%
growth inhibition (GI50). All data represented the results
of triplicate experiments.
Immunoblot and co-immunoprecipitation analysis
Western blotting and co-immunoprecipitation were done
as described previously [3]. Primary antibodies used: mouse
anti-Nek2 and mouse anti-Mcl-1 (BD Pharmingen, San
Diego, CA); rabbit anti-Hec1 (GeneTex, Inc., Irvine, CA);
mouse anti-actin (Sigma); mouse anti-P84 and mouse
anti-RB (Abcam, Cambridge, MA); rabbit anti-Cleaved
Caspase3, rabbit-anti-Cleaved PARP, rabbit anti-XIAP, and
mouse anti-P53 (Cell Signaling Technology, Boston, MA);
mouse anti-Bcl-2 (Santa Cruz); mouse anti-α-Tubulin
(FITC Conjugate; Sigma).
For co-immunoprecipitation, cells were lysed in buffer
(50 mM Tris (pH 7.5), 250 mM NaCl, 5 mM EDTA
(pH 8.0), 0.1% Triton X-100, 1 mM PMSF, 50 mM NaF,
and protease inhibitor cocktail (Sigma P8340)) for 1 hour
then incubated with anti-Nek2 antibody (rabbit, Rockland)
or IgG as control (rabbit, Sigma-Aldrich, St. Louis, MO) for
4 hours at 4°C, collected by protein G agarose beads
(Amersham) and processed for immunoblotting.
Immunofluorescent staining and microscopy
For quantification of mitotic abnormalities, cells were
grown on Lab-Tek® II Chamber Slides, washed with PBS
buffer (pH 7.4) before fixation with 4% paraformalde-
hyde. Following permeabilization with 0.3% Triton X-100,
cells were blocked with 5% BSA/PBST and incubated with
anti-α-Tubulin antibodies. Then DAPI (4’,6’-diamidino-2-
phenylindole) staining was applied and cells were mounted
with ProLong® gold antifade (Life Technologies). Images
were examined with NIKON 80i microscope at 400×
or 1000x magnification and captured with Spot Digital
Camera and Spot Advanced Software Package (Diagnostic
Instruments, Sterling Heights, MI). The percentage of cells
with mitotic abnormalities was calculated by the number of
the cells showing the abnormal mitotic figures (including
chromosomal misalignment and formation of multipolar
spindles) divided by the total number of mitotic cells
counted. A minimum of 500 cells from randomly selected
fields were scored per condition per experiment.
Mouse xenograft model
The procedure was adapted from published protocol [3]
and were in accordance to the Institutional Animal
Care and Use Committee of DCB. C.B-17 SCID mice
(6-7 weeks, 21-24 g) (Biolasco, Taipei, Taiwan) were
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and males were for MDA-MB-231. Cells were injected
subcutaneously into the flank in 50% matrigel solution
(BD Biosciences, San Jose, CA). 1×107, 3×106, and
6×106 implanted cells/mouse was used for Huh-7,
Colo-205, and MDA-MB-231, respectively. Treatment
initiated when tumor volume reached 150 mm3. For
Colo-205 and Huh-7, mice were treated with vehicle
control (10% DMSO 25% PEG200) per oral PO/BID/28 -
cycles in total. For Huh-7, a dose increase was incurred
on day 4 to increase efficacy. For Colo205, a dose de-
crease was incurred on day 13 to decrease body weight
loss. For MDA-MB-231, mice were treated with vehicle
control (5% DMSO, 10% Cremophor, 85% water for
Injections (WFI)) per oral PO/BID/28 cycles in total, or
TAI-1 formulated in vehicle (20 mg/kg intravenously IV/
QDx28 cycles or 150 mg/kg per oral PO/BID/28 cycles
in total). Tumor size were measured with digital calipers
and volume calculated using the formula (L x W x W)/
2, of which L and W represented the length and the
width in diameter (mm) of the tumor, respectively. Body
weights and tumor growth were measured twice a
week. Mean tumor growth inhibition of each treated
group was compared with vehicle control and a tumor
growth inhibition value calculated using the formula:
[1-(T/C) ×100%] (T: treatment group, C: control group
tumor volume).
Pilot toxicology study in mice
A sub-acute toxicology study was performed for TAI-1.
Female C.B-17 SCID mice (7 weeks old) were used in
this study. Mice were divided into four treatment
groups: vehicle control (10% DMSO, 25% PEG200, 65%
double distilled H2O), test article (in vehicle) at 7.5, 22.5,
and 75.0 mg/kg, and all mice were treated twice a day by
oral administration for 7 days (n = 8 for each group).
Body and organ weights were measured. Blood were
collected by cardiac puncture and serum analyzed for
complete blood count and biochemical indices.
In vitro kinase assay
Inhibition of kinase activity by test compound was esti-
mated by [33P] labeled radiometric assay. 20 kinase as-
says (Millipore) were adapted. The kinase reaction was
performed according to individual manual with minor
modification. In brief, each test compound was evaluated
at two concentrations (10 mM and 1 mM) in duplica-
tion. The kinase reaction were initiated by enzyme
addition, stopped at indicated time by the addition of 3%
phosphoric acid, harvested onto a filter plate by using a
unifilter harvester (PerkinElmer), and counted by using
TopCount (PerkinElmer). The results were the average
of duplicate measurements and expressed as percentage
inhibition (compound treatment versus DMSO control).Cardiac toxicology study - hERG binding assay
[3H]Astemizole competitive binding assays are per-
formed to determine the ability of compounds to dis-
place the known radioligand [3H]-astemizole from the
hERG potassium channels, following standard protocol
with minor modifications. In brief, assays were per-
formed in 200 μl of binding buffer (50 mM HEPES,
pH 7.4, 60 mM KCl, and 0.1% BSA) containing 1.5 nM
of [3H]astemizole, 3 μg/well of hERG membrane protein
(PerkinElmer), and TAI-1 (in 1% DMSO final concentra-
tion) at 27°C for 60 min. Nonspecific binding (NSB) was
determined in the presence of 10 μM astemizole. IC50
assay for TAI-1 contained 8 concentration points with 10-
fold serial dilution in triplicate. Binding was terminated by
rapid filtration onto polyethyleneimine-presoaked, buffer-
washed UniFilter-96, and GF/C (Perkin Elmer) using a
vacuum manifold (Porvair Sciences). Captured radiolabel
signal was detected using TopCount NXT (Perkin Elmer).
The data were analyzed with nonlinear curve fitting soft-
ware (PRISM, Graphpad) and IC50 value (defined as the
concentration at which 50% of [3H]-astemizole binding is
inhibited) was calculated. All results are derived from two
independent experiments.
Drug-drug synergy experiments
Interaction (synergy, additive, antagonistic activities)
between Hec1 inhibitor TAI-1 and anticancer drugs
(sorafenib, doxorubicin, paclitaxel, and topotecan) were
evaluated using standard assays. Twenty-four hours after
seeding, cells were treated with TAI-1, the other testing
drug, or in combination. For combination testing, TAI-1
or the other testing drugs were added to plate in tripli-
cate wells in ratios of GI50 (GI50A: GI50B), and cells are
incubated in drug-treated medium for 96 h and cell
viability determined by MTS. Synergy was determined





where CA,X and CB,X are concentrations of drug A and
drug B used in combination to achieve x% drug effect.
ICx,A and ICx,B are concentrations for single agents to
achieve the same effect. All data represent results of
triplicate experiments (and data on mean of three separ-
ate determinations had variations of less than ±20%).
Gene silencing by siRNA transfection
Cells were seeded onto 96-well plates and transfected
with siPort NeoFx transfection method (Ambion, Inc.,
TX, USA) according to manufacturer’s instructions.
Cells were cultured for 24 h and treated with compound.
SiRNA from two different sources were used to confirm
results. At least two independent experiments are used
Figure 1 Structure of Hec1 Inhibitor TAI-1.
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(#4390843, Ambion, Inc., Austin, TX, USA or #6568 s,
Cell Signaling Technology or sc-37007, Santa Cruz
Biotechnology), RB siRNA (Silencer Select ID:s523,
Ambion or sc-29468, Santa Cruz Biotechnology), and
P53 siRNA (#6231 s, Cell Signaling Technology, or
sc-29435, Santa Cruz Biotechnology) were employed.
The sequences of these control siRNAs are detailed in
the manufacturer websites.
Quantitative real-time RT-PCR
Total RNA was isolated with Quick-RNA miniPrep
(Zymo Research, Irvine, CA, USA). Reverse transcription
and quantitative real-time PCR was performed on ABI
Prism 7500 (PE Applied Biosystems, TX, USA) using the
One-Step SYBR ExTaq qRT-PCR kit (Takara, Shiga,
Japan) according to manufacturer’s instructions. The fol-
lowing primers were used:
for GAPDH
5′-GGTTTACATGTTCCAATATGATTCCA-3′ (for-








Gene expression in clinical samples–data from databases
NDC80 (Hec1) gene expression data in non-small
cell lung cancer (NSCLC) were retrieved from publicly
available database (Gene Expression Omnibus-GSE8894,
GSE3141 and GSE37745). Gene expression intensities
were normalized with quantile normalization. NDC80
expression between adenocarcinoma and squamous car-
cinoma was compared for all three different datasets.
Eight genes known to associate with NDC80 were iden-
tified (18, 27). One way hierarchical clustering analysis
for adenocarcinoma and squamous carcinoma of NSCLC
was conducted by using R package software (http://
www.r-project.org/).
Results
Hec1 inhibitor TAI-1 is highly potent with a wide anti-
cancer spectrum
The initial small molecule hits identified by Drs. Chen in
Dr. WH Lee’s laboratory, INH1 and INH2, had micro-
molar potency on cancer cell lines [3,11,12]. Through
medicinal chemical efforts to modify the hit structure,
we have significantly improved the potency of the Hec1-
targeted compound to low nanomolar level. The new
compound, TAI-1, has a GI50 of 13.48 nM (K562 cells),
which is close to 1000 times improvement in potencycompared to INH1 (GI50 = 11.7 μM) (14). To characterize
the potency of the new compound, TAI-1 (Figure 1), a
series of cancer cell lines were tested. The screen includes
31 cancer cell lines, is comprise of 12 cell lines from the
NCI-60 panel, and includes breast cancer, leukemia, liver,
lung, colon cancer, cervical cancer, prostate cancer and
bone cancer with various cellular characteristics. Growth
inhibition was quantitated with established MTS assay. As
summarized in Table 1, TAI-1 inhibits cellular growth at
nM levels for the majority of cancer cell lines screened.
To determine the activity of TAI-1 in multidrug resist-
ant (MDR) cell lines, established MDR cell lines were
tested. MES-SA/Dx5 and NCI-ADR-RES are resistant to
doxorubicin and paclitaxel, while K562R cells are resist-
ant to imatinib. TAI-1 was active in these cell lines
showing nM GI50 (Table 2).TAI-1 targets the Hec1-Nek2 pathway and induces
apoptotic cell death
To confirm the mechanism of action of TAI-1, we used
established methods to evaluate the interaction of Hec1
and Nek2 and the consequences of disruption of inter-
action of the proteins [3]. Co-immunoprecipitation study
shows that TAI-1 disrupted the binding of Nek2 to Hec1
in TAI-1-treated cells (Figure 2A). Disruption of Nek2
binding to Hec1 was shown to lead to degradation of
Nek2 [3], and this was also confirmed for TAI-1 (Figure 2B).
In addition, previous study also show that disruption of
Hec1-Nek2 interaction leads to misaligned chromosomes.
Treatment of cells with TAI-1 induced a time-dependent
increase in the proportion of cells with chromosomal
misalignment in cells (Figure 2C and D). These results are
consistent with the phenotypic consequences of the original
hit compound INH1 and show that TAI-1 targets Hec1-
Nek2 interactions.
The cell death pathway was evaluated with apoptotic
markers. Results show that TAI-1 induces cancer cell
death through the induction of cleavage of apoptotic
proteins Caspase 3 and PARP and degradation of anti-
apoptotic proteins MCL-1 and suggests that TAI-1 leads
to activation of the apoptotic pathways (Figure 2E).
Table 1 Characteristics of cell lines screened in Hec1 inhibitor drug assays
Cell lines Cell type RB P53 GI50 (nM)
Strong sensitivity (GI50 < 50 nM) K562 Chronic myeloid leukemia WT Mut 13








RPMI8226 Acute myeloid leukemia Mut Mut 27




HCT116 Colorectal carcinoma Low WT 39




Moderate sensitivity (50 nM < GI50 < 100 nM) PC3 Prostate cancer WT Null 60
MCF7 Breast, metastatic-pleural,
invasive ductal carcinoma
WT Heterogenous. WT 64







Huh7 Hepatocellular carcinoma WT Mut 84
BT474 Breast, primary, invasive
ductal carcinoma
WT Mut 86
PLC/PRF/5 Hepatocellular carcinoma WT Inactivated 92
Hep3B Hepatocellular carcinoma No Deletion 96
Low sensitivity (100 nM < GI50 < 1 μM) U2OS Osteosarcoma Less active WT 139
Hs578T Breast, metastatic, invasive
ductal carcinoma
WT Mut 143
MV4-11 Acute myeloid leukemia WT Mut 231
RS4;11 Acute myeloid leukemia WT Mut 254
HepG2 Hepatocellular carcinoma WT WT 273
MOLM-13 Acute myeloid leukemia WT Mut 315
Resistant (GI50 > 1 μM) A549 Non-small cell lung cancer WT WT >10 μM
HCC1954 Breast, invasive ductal carcinoma Mut WT >10 μM
MDA-MB-361 Breast, metastatic-brain, adenocarcinoma WT No >10 μM
MOLT-4 Acute lymphoblastic leukemia WT WT >30 μM
N87 Gastric cancer WT WT >30 μM
*WT, wild type; Mut, mutated.
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xenograft models
To evaluate the in vivo efficacy of TAI-1, xenografted mice
models of human tumor cancer cell lines were used. Well-
established Huh-7 (hepatocellular carcinoma), Colo205
(colorectal adenocarcinoma from metastasis and ascites),
and MDA-MB-231 (triple negative breast cancer cell line)derived models were used. Implanted tumors are allowed
to grow to 100-150 mm3, then mice were orally adminis-
tered TAI-1, since the compound was to be developed as
an oral drug. TAI-1 led to significant tumor growth retard-
ation in Huh-7 and modest tumor inhibition was noted tor
the Colo205 and MDA-MB-231 models (Figure 3 left
panels). Intravenous route was also evaluated in MDA-MB-
Table 2 GI50s of TAI-1 and commerically available drugs
in cell lines
Cell line TAI-1 GI50 (nM)
Drug resistant cancer cell lines MEX-SA/Dx5 35
NCI/ADR-RES 29
K562R 30
Normal cell lines WI-38 >10 μM
RPTEC >10 μM
HuVEC > 9 μM
HAoSMC > 9 μM
*N.D, not determined.
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and intravenous doses did not lead to any loss in body
weight (Figure 3 right panels) or any observed clinical
signs.
Toxicity studies of TAI-1 in rodents
To determine potential toxicity of TAI-1 in orally effica-
cious treatment regimen, a pilot toxicity study was per-
formed in mice at oral doses corresponding to that used
in xenograft studies. The same species and gender of
mice were used and dosed at the corresponding doses
for 7 days. Daily observation of clinical signs (pain,
locomotion/body stature, skin/coat abnormalities) and
defecation changes were performed and no changes were
noted. Body weight, complete blood count, and serum
biochemistry were monitored before and after dosing
(Day 0 and Day 7). Postmortem observation of the
gastrointestinal tract, liver, kidney, spleen, lung and heart
were performed and organ weights were measured. No
body weight or organ weight loss was noted (Figure 4A
and B). No adverse effects on liver and kidney indices
were noted (Figure 4C-D). In addition, no changes in
red and white blood cells plasma indices were noted at
the efficacy doses tested (Additional file 1: Table S1 and
Table S2). TAI-1 shows no adverse effect under effica-
cious oral dose levels.
Safety studies of TAI-1
The clinical application of anticancer drugs is often lim-
ited by their non-specific target activity leading to organ
toxicity and other side effects. To evaluate the prelimin-
ary safety profile of TAI-1, we investigated the inhibitory
potential of TAI-1 against normal cell lines, against a
panel of kinases, and also on its binding to hERG, a
known target for cardiac toxicity.
To determine the cancer cell specificity of TAI-1, nor-
mal cell lines were tested. In normal fibroblast (WI-38),
renal tubule cells (RPTEC), umbilical vein cells (HuVEC)
and aortic smooth muscle (HAoSMC) cell lines, TAI-1
had a GI50 of more than 1000 times that of cancer cell
GI50 (Table 2), showing a high therapeutic index.When screened against a panel of known kinases,
TAI-1 has no inhibitory effects against these targets
(Figure 5A), confirming the specificity of TAI-1 to Hec1
and against these kinases targets.
We have tested TAI-1 with the hERG assay, which as-
sesses the most common mechanism involved in drug-
induced prolongation of QT interval, which increases
the risk of ventricular tachyarrhythmia through the in-
hibition of potassium ion flow and may lead to sudden
cardiac death [13,14]. The hERG channel assay revealed
a competition IC50 1000 times that of cancer cell GI50
(Figure 5B), suggesting that this compound has little po-
tential of cardiac toxicity through the hERG channel at
the therapeutic doses. In summary, TAI-1 exhibits high
specificity to cancer cells and to target and shows no
cardiac toxicity by hERG.
TAI-1 is synergistic with some commonly used
cytotoxic drugs
Synergy with currently available anti-cancer drugs dem-
onstrates possibility of a compound to be utilized in
combinatorial treatment approach. To determine pos-
sible synergistic combinations, the effects of TAI-1 in
combination with various cytotoxic drugs were evalu-
ated. TAI-1-sensitive cancer cells were treated with an
appropriate ratio of doses of cytotoxic agents to TAI-1
determined by corresponding drug GI50, as shown in
Table 3 (Drug 1: TAI-1 GI50 ratio) and MTS assay used
to determine cellular proliferation. Combination index
(CI) was calculated from the GI50s obtained to represent
additive (CI = 1), synergistic (CI < 1) or antagonistic (CI > 1)
effects. TAI-1 was synergistic with doxorubicin, topotecan,
and paclitaxel, but not synergistic with sorafenib and the
novel src inhibitor KX-01 [15] (Table 3).
Role of RB and P53 in TAI-1 cellular sensitivity
TAI-1 is active on a wide spectrum of cancer cell lines;
however, 5 cell lines were resistant to TAI-1 (Table 1).
To explore possible resistance mechanisms of TAI-1, we
evaluated the role of retinoblastoma protein RB (a Hec1
interacting protein [4,16] through which Hec1 was
discovered), and P53, another oncogene in the same
category as RB, which might provide a cellular escape
mechanism. The RB and P53 tumor suppressors are
both critical players in DNA damage checkpoint [17]. A
cross-tabulation comparison of the RB [17-22] and P53
[20,22-28] gene status versus sensitivity to TAI-1 (in this
case, response is identified as GI50 of < 1 μM, n = 19)
revealed an interesting pattern of response to Hec1
inhibitor TAI-1 (Table 1).
To quantitate Hec1 protein expression levels, we ana-
lyzed the expression levels of the Hec1 protein by west-
ern blotting and quantitated protein levels using HeLa
as standard, and high expression determined as > 50%
Figure 2 TAI-1 Disrupts Hec1-Nek2 interactions, induces chromosomal misalignment and induces apoptosis of cancer cells. (A) K562
cells were treated with 500 nM TAI-1, lysates immunoprecipitated with anti-Nek2 antibody were probed for Hec1 by western blotting to deter-
mine interaction. (B) K562 cells were treated with TAI-1 at 1 μM for the indicated time points and collected for immunoblotting of Hec1 and
Nek2. (C) MDA-MB-468 cells treated with 1 μM TAI-1 were immunofluorescent stained for DNA and mitotic spindle. (D) Metaphase cells were
counted for percentage of cells with misaligned chromosomes. (E) Lysates of HeLa treated with TAI-1 for 8 or 24 hours were western blotted for
apoptotic markers caspase3 and PARP and anti-apoptotic markers MCL-1, XIAP, and BCL-2. Actin was used as loading control.
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showing a good cellular proliferative response to TAI-1
(as defined by GI50 < 1 μM) had a much higher level of
expression of Hec1 compared with resistant cell lines(GI50 > 1 μM) (p < 0.0001). Table 4 shows the relation-
ship between the expression of Hec1 and the status of
the markers. High level expression of Hec1 was associ-
ated with a better response to the Hec1 inhibitor TAI-1
Figure 3 TAI-1 inhibits growth of multiple tumor types in xenografted mouse models. Nude mice engrafted with cancer cell lines were
treated for 28 days either orally or intravenously as indicated and tumor size measured daily. Huh-7 (A), Colo205 (B), and MDA-MB-231 (C) cells
were used. Left panel:% tumor inhibition. Right panel:% body weight.
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to 1/3 of the low Hec1 expression cell lines, p < 0.01).
In the same analysis, a higher proportion of wild type
P53 cell lines showed more resistance to Hec1 inhibitor
TAI-1 compared with those with mutant (including
deleted gene) P53 (p < 0.005, Table 4). When the Hec1
expression level was combined with the P53 gene status
(wild type vs. mutant/deleted), the correlation was more
tight statistically (p < 0.0001, Table 4).In the analysis of the impact of the RB gene (either
hypophosphorylation or deletion), the correlation with
response to the Hec1 inhibitor TAI-1 was not estab-
lished in this database. However, when combined with
the Hec1 expression level (dual markers), the correlation
with response to TAI-1 was more tight (p < 0.005,
Table 4).
When the two markers P53 and RB genes were com-
bined (i.e. the presence of an aberrant P53 and/or RB
Figure 4 7-day toxicology study of TAI-1 in mice shows no significant change in body weight, organ weight, and plasma indices. C.B-
17 SCID mice (n = 8) were orally administered TAI-1 for 7 days and body weights (A) and organ weights (B) were measured. Liver (C) and kidney
(D) plasma indices were determined.
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correlation was also very strong (p < 0.005, Table 4).
When combined with the Hec1 expression (i.e. Hec1 ex-
pression level combined with the presence of aberrant
P53 and/or RB gene), the correlation was very tight
(p < 0.0001, Table 4).In vitro inhibition of RB and P53 and cellular sensitivity
to TAI-1
To determine the role of RB and P53 in TAI-1 cellular
sensitivity, in vitro siRNA knockdown assays were per-
formed in cells carrying wild type RB and P53, respect-
ively. HeLa, which carry mutated RB and mutated P53,
Figure 5 TAI-1 does not inhibit a number of kinases and hERG at below 10 μM. (A) Inhibition of kinases were performed with 10 μM TAI-1
with standard assays. (B) hERG inhibition was determined with 10 μM TAI-1. Results show good cardiac safety of TAI-1.
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assays.
To determine the role of RB in TAI-1 cellular sensitiv-
ity, siRNA to RB was used in cell lines carrying wild type
RB, including MDA-MB-231, K562, ZR-75-1, T47D,
A549, and HCT116. After siRNA treatment, cells were
treated with TAI-1 and analyzed at 48 hours after TAI-1
treatment with MTS assay. In the first experiment, a full
scale GI50 was assessed in MDA-MB-231 cells following
siRNA transfection. A 20% decrease in RB RNA levels
was seen in conjunction with a 7% decrease of GI50 inTable 3 Synergistic effects of TAI-1 with cytotoxic agents
Drug Cell lines Drug 1 GI50 (nM) TAI-1 GI50 (nM)
Doxorubicin K562 36 44
MDA-MB-468 27 34
Huh7 183 84
Topotecan MDA-MB-231 347 43
MDA-MB-468 11 34
Paclitaxel Huh7 94 84
MDA-MB-231 5 42
K562 10 41
Sorafenib Huh7 (liver) 4501 84
Hep3B (liver) 3676 104
KXO1 Huh7 (liver) 27 84
*Combination index: 1 = additive, < 1 = synergy, > 1 = antagonistic.(Figure 7A). In subsequent experiments with other cell
lines (Figure 7B), single dose inhibition was assessed.
Using the protocol described in the Methods section, we
were able to show the decreased RB protein and this
was associated with a 10 ~ 25% enhancement in cancer
cell proliferation inhibition (Figure 7B). In experiments
with HeLa as a control (known to have RB mutation),
siRNA incubation showed a reduction in the expression
of the mutant RB but no effect on the cellular sensitivity to
TAI-1. To ensure that this effect was not RB-siRNA












Figure 6 TAI-1 GI50s correlates with Hec1 protein expression in
cancer cell lines. Asynchronously maintained cell lines are lysed
and their total protein immunoblotted for expression levels of Hec1.
Hec1 protein expression levels are quantitated and expressed in%
relative to HeLa expression levels.
Table 4 Predictive values of biomarkers for Hec1 therapy
Hec1 expression Hec1 +/- P53 expression
Total Mut WT Total Mut WT
Sensitive 17 16 1 Sensitive 25 25 0
Resistant 2 0 2 Resistant 5 1 4
P value < 0.01 P value < 0.0001
P53 expression Hec1 +/- RB expression
Total Mut WT Total Mut WT
Sensitive 25 22 3 Sensitive 25 18 7
Resistant 5 1 4 Resistant 5 0 5
P value < 0.005 P value < 0.005
RB expression Hec1 +/- RB +/- P53 expression
Total Mut WT Total Mut WT
Sensitive 25 7 18 Sensitive 25 25 0
Resistant 5 0 5 Resistant 5 1 4
P value = 0.3 P value < 0.0001
RB +/- P53 expression
Total Mut WT
Sensitive 25 23 2
Resistant 5 1 4
P value < 0.005
NOTE: Drug-sensitive (TAI-1 GI50 < 300 nM); Drug-resistant (TAI-1 GI50 > 300 nM);
Mut (high Hec1 protein expression level (> 50% HeLa expression), mutated/aberrant
RB, or mutated/aberrant P53); WT (low Hec1 protein expression level (< 50% HeLa
expression), wild type RB, or wild type P53). 2-tailed t test is utilized to determine
significance in P values.
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sults not shown). Knockdown of RB in wild type RB cancer
cells lead to increased sensitivity to TAI-1.
To determine the role of P53 in TAI-1 cellular sensitivity,
siRNA to P53 was used in cell lines carrying wild type P53,
including A549, HCT116, ZR-75-1, and U2OS, were used
for P53 knockdown assays. The same methods as RB study
were used. As shown in Figure 8A, a 60 ~ 80% decrease in
P53 RNA levels lead to 30 ~ 50% decrease of GI50 in A549
and HCT116 cells, and this was associated with a 10 ~ 20%
increase in the enhancement of cancer cell proliferation in-
hibition (Figure 8A and B). Again, in HeLa cells, which has
a mutant P53 and served as a control, siRNA also inhibit
the expression of mutant P53 RNA but had no effect on
the cellular proliferation inhibition activity of TAI-1. Fur-
thermore, to ensure that the effect is not siRNA sequence-
specific, knockdown with a different P53-siRNA sequence
was conducted and showed similar results (results not
shown). Knockdown of P53 lead to increased cellular
sensitivity to TAI-1 in the cells carrying wild type P53.
These results indicate that the status of RB and P53 may
affect the activity of Hec1-targeted inhibitor TAI-1 on can-
cer cells, and cells with a loss of functional RB or P53 may
have an increased sensitivity to Hec1-targeted inhibitors.
Differential Hec1 expression in clinical cancer subtypes
Genome-wide expression profile analysis has shown that
Hec1 is upregulated in lung, colorectal, liver, breast, and
brain tumors and that Hec1 expression correlates with
tumor grade and prognosis [4,9]. To determine whether
HEC1 expression varies between cancer subtypes from
the same tissue or organ, the gene expression data of
NDC80 (HEC1) between adenocarcinoma and squamous
carcinoma was studied for lung cancer. As shown in
Figure 9A, NDC80 expression is significantly higher in
squamous cell carcinoma of lung than adenocarcinoma
in all three independent datasets. One way hierarchical
cluster analysis consistently showed that NDC80, NEK2,
NUF2 and SPC25 were reproducibly clustered together
in three different gene expression datasets (Figure 9B).
All these four genes showed higher expression in squa-
mous cell carcinoma of lung. The results indicate that
different subtypes of lung cancer could respond differ-
ently to the treatment of Hec1 inhibitor. The predictabil-
ity of response to Hec1-targeted treatment according to
Hec1 associated gene expression remains to be further
studied; however, our results suggest such consideration
for HEC1 or related gene expression may be an import-
ant factor in the design of personalized Hec1-targets
treatment of cancers.
Discussion
This study explored the potential of the improved anti-
cancer agent targeting Hec1 for clinical development
Figure 7 Efficient knockdown of RB in cancer cells increases cellular sensitivity to TAI-1. (A) MDA-MB-231 cells which carry wild-type
RB were transfected with control siRNA (siControl) or siRNA of RB (siRB) for 24 hours and treated with TAI-1 (starting dose 100 μM, 3x serial
dilution), incubated for 48 hours and analyzed for viability with MTS. Cellular sensitivity is expressed in GI50 (nM) and RNA from transfected
cells were analyzed for RB RNA level by quantitative real time PCR. SiRB reduced GI50 of compound in cells. (B) Selected cell lines which carry
wild type RB (MDA-MB-231, K562, ZR-75-1, T47D, A549, HCT116) or mutated RB (HeLa, as control) were transfected with siRB and treated with
TAI-1, incubated for 48 hours and analyzed for viability with MTS. Cellular sensitivity is expressed as% growth inhibition and cell lysates from
transfected cells were collected and RB protein levels determined by western blotting. Shown are representative results from at least two
independent experiments.
Huang et al. Journal of Experimental & Clinical Cancer Research 2014, 33:6 Page 12 of 17
http://www.jeccr.com/content/33/1/6
Figure 8 Efficient P53 knockdown in cancer cells increases cellular sensitivity to TAI-1. (A) A549 and HCT116 cells which carry wild-type
P53 were transfected with control siRNA (siControl) or P53 siRNA (siP53) for 24 hours and treated with TAI-1 (starting dose 100 μM, 3x serial
dilution), incubated for 48 hours and analyzed for viability with MTS. Cellular sensitivity is expressed in GI50 (nM) and RNA from transfected cells
were analyzed for P53 RNA level by quantitative real time PCR. SiP53 reduced GI50s of compound in cells. (B) Selected cell lines which carry wild
type P53 (A549, HCT116, ZR-75-1, U2OS) or mutated P53 (HeLa, as control) were transfected with siP53, treated with TAI-1 and analyzed for viability with
MTS. Cellular sensitivity is expressed as% growth inhibition and cell lysates from transfected cells were collected and P53 protein levels determined by
western blotting.
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for response and clinical relevance was evaluated using
in vitro, in vivo, and database analysis methods.
Ever since Hec1 was discovered and characterized, the
possibility that this may be a good molecular target wasdiscussed. Hec1 is an oncogene that when overexpressed
in transgenic mice leads to tumor formation [5]. The
differential expression profile of Hec1 in cancer cells in
comparison to normal non-actively dividing cells further
supports the suitability of this target for anticancer
Figure 9 Differential expression of NDC80 (Hec1) and genes associated with NDC80 between subtypes of non-small cell lung cancer.
(A) NDC80 (Hec1) (Affymetrix Probeset ID 204162_at) expression between adenocarcinoma and squamous cell carcinoma of lung in three
different independent datasets (GSE8894, GSE3141 and GSE37745). The unit of Y axis is logarithm of expression intensity to the base 2. ANOVA
was used to compare these two subtypes of NSCLC. (B) One way hierarchical clustering analysis of NDC80 gene and genes associated with
NDC80 for subtypes of NSCLC in the same three independent datasets. The results consistently showed up-regulated expression of NDC80 and
its closely associated genes (SPC25, NUF2 and Nek2) in squamous cell carcinoma of lung. Green: adenocarcinoma. Yellow: squamous cell
carcinoma. The heat map scale is mean ± 2SD.
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with largely improved potency range enabling the pre-
clinical development of a Hec1 targeted small molecule.
The structure-activity relationship is demonstrated for
over 200 analogues of the Hec1-targeted small molecule
(Huang et al, manuscript in preparation).
The improved Hec1-targetd small molecule TAI-1 in-
hibits the growth of a wide spectrum of cancer cell lines
in vitro. Interestingly, a small number of cell lines were
resistant to TAI-1, suggesting that there may be changes
in signaling pathways that allow cells to bypass Hec1 in-
hibitor induced cell death. This observation prompted
our further exploration of markers for TAI-1 response,
which may have clinical implications for personalized
therapy. A number of known cellular factors were
assessed for their impact on the cellular response toTAI-1. The expression of Hec1, its interacting partner
RB [29], and P53, a tumor suppressor like RB, were
evaluated based on possible crosstalk of pathways. The
profile in Table 1 shows a possible association of the sta-
tus of the tumor suppressors with cellular sensitivity to
TAI-1. Analysis of the three factors indicate that the
participation of RB is nominal (Table 4), however, the
in vitro siRNA studies show that RB may play a role in
TAI-1 sensitivity (Figure 7). The impact of RB remains
to be clarified in future biomarker studies. In contrast,
the combined markers Hec1 and P53 showed a signifi-
cant impact on cellular sensitivity to TAI-1 (Table 4). In
addition, the role of P53 is further supported by the
in vitro siRNA knockdown studies (Figure 8). Although
these are very interesting findings, a larger study to
allow multivariate analysis will be necessary for more
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of the current study. Nevertheless, these findings provide
a rationale for the building of the parameters for re-
sponse into future clinical studies for Hec1 inhibitors, in
particular TAI-1, and analogues of TAI-1.
In contrast to in vitro cell line studies, the in vivo
models demonstrated efficacy but doesn’t reflect the po-
tency from in vitro studies. Administration of drug to
animal models, in comparison to cell lines in culture,
adds another level of complexity due to possible variabil-
ity in drug absorption levels due to barriers encountered
during oral administration, such as enzymatic degrad-
ation, pH sensitivity, drug pumps in the gastrointestinal
tract, etc.; hence, the efficacy values between the in vivo
models and in vitro models cannot be directly compar-
able. It is therefore only appropriate to use these prelim-
inary xenograft models to determine efficacy but not to
efficacy doses directly to in vitro GI50. Furthermore, bet-
ter comparison of the efficacy doses between xenograft
models should be designed so absorption levels are con-
trolled and formulation of the vehicle for administration
is optimized. Note that we are the first to evaluate the
oral efficacy of Hec1-targeted inhibitors as an anticancer
agent and demonstrate efficacy of the improved Hec1-
targeted compound in human liver, colon and breast
in vivo tumor models. Even though the great leap in
in vitro potency doesn’t correlate well with the in vivo
efficacy, this study provides a basis for the pharmaceut-
ical development of a Hec1-targeted small molecule
based on the significant improvement in in vitro efficacy,
which translates to a clinically applicable oral dosage.
The pharmacological parameters, such as oral absorp-
tion, and compound solubility remains to be overcome
by further modifications to the core structure and ex-
ploration of dosing formulations through the efforts of
medicinal chemists and formulation experts.
The safety of TAI-1 was evaluated with activity in nor-
mal cell lines, hERG inhibition and a pilot toxicity study.
The activity in normal cell lines suggests that TAI-1 has
high cancer cell specificity and a high therapeutic index.
In combination with hERG inhibition assay, the in vitro
evaluation shows that TAI-1 is safe as an anticancer
agent with little liability on cardiac toxicity. Further-
more, in vivo toxicity studies in the same species of mice
as the xenograft studies showed no body weight loss and
no changes in organ weight and plasma indices. These
athymic mice used for in vivo modeling were good cor-
relation of the toxicity incurred at efficacy doses in the
xenograft models, but were unable to show immunosup-
pression, a common side effect of chemotherapeutics. In
rodent with intact thymus, dosing of TAI-1 lead to a
dose-dependent decrease of thymus weights and a slight
decrease of spleen weights, but did not showed dose-
dependent changes in blood indices, including whiteblood cells, due to TAI-1 (Additional file 2: Figure S1). It
should be noted that it is also possible that the lack of
body weight loss and hematological effects may not be
evident in only 7 days, and toxicity studies dosed for
longer period of times may be able to further determine
the long term effects of TAI-1. In contrast to the 7-day
toxicity study conducted independently of the xenograft
studies in SCID mice, xenograft studies seemed to show
a modest body weight loss (up to 13.5% at day 7, n = 6)
during dosing (Figure 3). Since this effect was not evi-
dent in the independently conducted toxicity studies in
the same species of mice (0% change at day 7, n=8), the
body weight loss is suggested to be nonspecific to the
compound. The body weight loss may be related to the
tumor burden or different tumor xenograft interactions,
since the change varied between models (11.5% for
Huh-7 and 13.5% for Colo205 at day 7). The influencing
factors of body weight loss in the xenograft models re-
mains unclear, and further parallel designs of xenograft
and toxicity studies may help determine the underlying
cause.
The translational implications were further explored
with studies in multi-drug resistant (MDR) cell lines,
synergistic studies, and clinical databases. The activity in
MDR cell lines was shown with other Hec1 analogues
(Huang et al., manuscript submitted) and is not specific
to the Hec1 analogue TAI-1. The activity in MDR cell
lines carry important clinical implications and suggests
that Hec1-targeted agents may be able to offered as a
treatment option to cancer patients who do not respond
to currently available anticancer agents, a major clinical
advance. A combinatorial approach incorporating anti-
cancer drugs targeting different pathway for treatment
regimens is often used to improve medical outcomes.
The synergistic effects of TAI-1 with commercial anti-
cancer agents suggest that TAI-1 or its analogues may
be very easily incorporated to current multi-drug treat-
ment regimens. A small pilot study using clinical data-
base analysis shows that Hec1 expression may correlate
with established patient subtypes, which may further aid
in the building of the parameters for response in clinical
applications. Further studies in the clinical development
of Hec-1 inhibitors will determine whether selection
based on these subtypes will aid in the identification
of patients who are more likely to respond to Hec1-
targeted therapy.Conclusion
In conclusion, this study demonstrates the potential of
the improved anticancer agent targeting Hec1 for clin-
ical utility. The potency, safety, and translational impli-
cations show that a Hec1-targeted small molecule agent
can be developed for clinical utility and that a variety of
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port clinical development.
Additional files
Additional file 1: Supplementary materials and methods. This file
includes the preparation of TAI-1, supplementary tables for toxicology
blood indices, and Additional file 2: Figure S1.
Additional file 2: Figure S1. 7-day toxicology study of TAI-1 in rats
with intact thymus shows reversible lower thymus and spleen weights
and no gastrointestinal changes. Toxicology thymus and spleen weights
and gastrointestinal results.
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